Alamar Biosciences, Inc. is a life sciences company dedicated to transforming the field of proteomics through the development of high-sensitivity protein detection technologies. The company's primary focus is on the early detection of diseases, particularly in the areas of oncology, neurology, and inflammatory conditions. Alamar's flagship technology, the NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) platform, is designed to provide ultra-high sensitivity and multiplexing capabilities, allowing researchers and clinicians to detect low-abundance biomarkers that were previously difficult to measure. This platform, along with the automated ARGO HT System, enables high-throughput analysis of the proteome from small sample volumes, such as blood or plasma. By bridging the gap between genomics and proteomics, Alamar Biosciences aims to provide a more comprehensive understanding of disease biology. Their tools are used by pharmaceutical companies and academic researchers to discover new biomarkers, accelerate drug development, and ultimately improve patient outcomes through earlier diagnosis and personalized therapeutic strategies.
No data found.